EGFR and non-small cell lung carcinoma: In recent years, a new generation of compounds capable of selectively targeting EGFR Ex20ins have been evaluated in a number of clinical trials involving NSCLC patients and two new targeted therapies have recently been approved by the US Food and Drug Administration (FDA) for the treatment of this previously undruggable molecular subtype of NSCLC.